Panacos Pharmaceuticals, Inc.
PANC · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Revenue | $180 | $284 | $1,049 | $1,337 |
| % Growth | -36.6% | -72.9% | -21.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $180 | $284 | $1,049 | $1,337 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $25,090 | $24,548 | $19,798 | $11,148 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12,840 | $17,431 | $8,045 | $2,158 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$76,772 | -$83,390 | -$86,778 | -$23,938 |
| Operating Expenses | -$38,842 | -$41,411 | -$58,935 | -$10,632 |
| Operating Income | $39,022 | $41,695 | $59,984 | $11,969 |
| % Margin | 21,678.9% | 14,681.3% | 5,718.2% | 895.2% |
| Other Income/Exp. Net | -$39,022 | -$41,695 | -$59,984 | -$11,969 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37,459 | -$38,110 | -$59,078 | -$12,038 |
| % Margin | -20,810.6% | -13,419% | -5,631.8% | -900.4% |
| EPS | -0.7 | -0.75 | -1.72 | -14.51 |
| % Growth | 6.7% | 56.4% | 88.1% | – |
| EPS Diluted | -0.7 | -0.75 | -1.72 | -14.51 |
| Weighted Avg Shares Out | 53,145 | 50,523 | 34,423 | 962 |
| Weighted Avg Shares Out Dil | 53,145 | 50,523 | 34,423 | 4,773 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $794 | $751 | $628 | $227 |
| EBITDA | -$38,228 | -$40,944 | -$39,938 | -$11,742 |
| % Margin | -21,237.8% | -14,416.9% | -3,807.2% | -878.2% |